首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >Ketorolac tromethamine transdermal gel: development, in vitro and in vivo evaluation.
【24h】

Ketorolac tromethamine transdermal gel: development, in vitro and in vivo evaluation.

机译:酮咯酸三甲胺透皮凝胶剂:开发,体外和体内评估。

获取原文
获取原文并翻译 | 示例
       

摘要

The authors developed and evaluated a transdermal gel formulation of ketorolac tromethamine (ketorolac) for the treatment of nociceptive somatic pain. The formulation was optimized for skin permeation enhancers, pH of the system, and dosage strength using in vitro and in vivo techniques. Of the various permeation enhancers evaluated, dimethyl sulfoxide (DMSO) and oleic acid were found to significantly increase skin permeation flux of ketorolac. The concentration of DMSO affected the rate as well as extent of transdermal absorption. Use of citric acid further improved the skin penetration of ketorolac. In vitro diffusion results indicated significant increase in drug permeation with increasing drug concentration. However, the same did not translate into higher skin permeation during in vivo study. Although the area under concentration time curve (AUC(0-t)) increased significantly with increasing dose, the effect on maximum serum concentration (C(max)) was insignificant. The formulation can be used for inflammatory pain management while avoiding gastric adverse events associated with oral ketorolac.
机译:作者开发并评估了酮咯酸氨丁三醇(ketorolac)的透皮凝胶制剂,用于治疗伤害性躯体疼痛。使用体外和体内技术对皮肤渗透促进剂,系统的pH值和剂量强度进行了优化。在评估的各种渗透促进剂中,发现二甲基亚砜(DMSO)和油酸可显着增加酮咯酸的皮肤渗透通量。 DMSO的浓度影响透皮吸收的速率和程度。柠檬酸的使用进一步改善了酮咯酸的皮肤渗透性。体外扩散结果表明,随着药物浓度的增加,药物渗透性显着增加。然而,在体内研究中,同样的结果并没有转化为更高的皮肤渗透性。尽管浓度时间曲线下的面积(AUC(0-t))随着剂量的增加而显着增加,但对最大血清浓度(C(max))的影响不明显。该制剂可用于炎症性疼痛的治疗,同时避免与口服酮咯酸有关的胃不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号